Endosonics
This article was originally published in The Gray Sheet
Executive Summary
FDA tells firm that its Oracle-Micro coronary balloon angioplasty-imaging catheter premarket approval application requires "additional data presentation and analysis" on patients currently enrolled in clinical trials, the company says. Endosonics previously reported that it submitted data answering all questions raised by the Circulatory System Devices Advisory Panel in conjunction with its April 1993 recommendation against approving the device ("The Gray Sheet" Jan. 10, I&W-12). FDA's new request is due to "recently implemented PMA clinical data presentation requirements," the company says, noting that it will file a PMA amendment containing the data "as soon as possible"
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.